John Strony

Sr. Director
Global Clinical Development of CVM, Johnson and Johnson Innovative Medicine
Raritan, New Jersey, United States

Presentation(s):

• OC 66.2 - Characterizing the Relationship between Milvexian Exposure, Efficacy, and Safety in Total Knee Replacement Patients to Support Milvexian Phase 3 Dose Selection.

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT